These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

328 related items for PubMed ID: 24983796

  • 1. The impact of symptom dimensions on outcome for exposure and ritual prevention therapy in obsessive-compulsive disorder.
    Williams MT, Farris SG, Turkheimer EN, Franklin ME, Simpson HB, Liebowitz M, Foa EB.
    J Anxiety Disord; 2014 Aug; 28(6):553-8. PubMed ID: 24983796
    [Abstract] [Full Text] [Related]

  • 2. The relationships between obsessive-compulsive symptom dimensions and cognitions in obsessive-compulsive disorder.
    Brakoulias V, Starcevic V, Berle D, Milicevic D, Hannan A, Martin A.
    Psychiatr Q; 2014 Jun; 85(2):133-42. PubMed ID: 24142072
    [Abstract] [Full Text] [Related]

  • 3. Hoarding symptoms and prediction of poor response to limbic system surgery for treatment-refractory obsessive-compulsive disorder.
    Gentil AF, Lopes AC, Dougherty DD, Rück C, Mataix-Cols D, Lukacs TL, Canteras MM, Eskandar EN, Larsson KJ, Hoexter MQ, Batistuzzo MC, Greenberg BD, Miguel EC.
    J Neurosurg; 2014 Jul; 121(1):123-30. PubMed ID: 24702323
    [Abstract] [Full Text] [Related]

  • 4. Use of factor-analyzed symptom dimensions to predict outcome with serotonin reuptake inhibitors and placebo in the treatment of obsessive-compulsive disorder.
    Mataix-Cols D, Rauch SL, Manzo PA, Jenike MA, Baer L.
    Am J Psychiatry; 1999 Sep; 156(9):1409-16. PubMed ID: 10484953
    [Abstract] [Full Text] [Related]

  • 5. Response of symptom dimensions in obsessive-compulsive disorder to treatment with citalopram or placebo.
    Stein DJ, Andersen EW, Overo KF.
    Braz J Psychiatry; 2007 Dec; 29(4):303-7. PubMed ID: 18200396
    [Abstract] [Full Text] [Related]

  • 6. The characteristics of unacceptable/taboo thoughts in obsessive-compulsive disorder.
    Brakoulias V, Starcevic V, Berle D, Milicevic D, Moses K, Hannan A, Sammut P, Martin A.
    Compr Psychiatry; 2013 Oct; 54(7):750-7. PubMed ID: 23587527
    [Abstract] [Full Text] [Related]

  • 7. Cognitive-behavioral therapy as an adjunct to serotonin reuptake inhibitors in obsessive-compulsive disorder: an open trial.
    Simpson HB, Gorfinkle KS, Liebowitz MR.
    J Clin Psychiatry; 1999 Sep; 60(9):584-90. PubMed ID: 10520976
    [Abstract] [Full Text] [Related]

  • 8. Symptom dimensions in obsessive-compulsive disorder: phenomenology and treatment outcomes with exposure and ritual prevention.
    Williams MT, Mugno B, Franklin M, Faber S.
    Psychopathology; 2013 Sep; 46(6):365-76. PubMed ID: 23615340
    [Abstract] [Full Text] [Related]

  • 9. Six-month outcomes from a randomized trial augmenting serotonin reuptake inhibitors with exposure and response prevention or risperidone in adults with obsessive-compulsive disorder.
    Foa EB, Simpson HB, Rosenfield D, Liebowitz MR, Cahill SP, Huppert JD, Bender J, McLean CP, Maher MJ, Campeas R, Hahn CG, Imms P, Pinto A, Powers MB, Rodriguez CI, Van Meter PE, Vermes D, Williams MT.
    J Clin Psychiatry; 2015 Apr; 76(4):440-6. PubMed ID: 25375780
    [Abstract] [Full Text] [Related]

  • 10. Cognitive-behavioral therapy vs risperidone for augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder: a randomized clinical trial.
    Simpson HB, Foa EB, Liebowitz MR, Huppert JD, Cahill S, Maher MJ, McLean CP, Bender J, Marcus SM, Williams MT, Weaver J, Vermes D, Van Meter PE, Rodriguez CI, Powers M, Pinto A, Imms P, Hahn CG, Campeas R.
    JAMA Psychiatry; 2013 Nov; 70(11):1190-9. PubMed ID: 24026523
    [Abstract] [Full Text] [Related]

  • 11. Association between miscellaneous symptoms and primary symptom dimensions among chinese adults with obsessive-compulsive disorder.
    Zhou Y, Cao X, Wang J, Gao R, Chen Y, Liu Y, Zhang Z, Wang Z, Storch EA, Fan Q.
    Psychiatry Res; 2019 Apr; 274():274-279. PubMed ID: 30825727
    [Abstract] [Full Text] [Related]

  • 12. Maintenance of Wellness in Patients With Obsessive-Compulsive Disorder Who Discontinue Medication After Exposure/Response Prevention Augmentation: A Randomized Clinical Trial.
    Foa EB, Simpson HB, Gallagher T, Wheaton MG, Gershkovich M, Schmidt AB, Huppert JD, Imms P, Campeas RB, Cahill S, DiChiara C, Tsao SD, Puliafico A, Chazin D, Asnaani A, Moore K, Tyler J, Steinman SA, Sanches-LaCay A, Capaldi S, Snorrason Í, Turk-Karan E, Vermes D, Kalanthroff E, Pinto A, Hamlett GE, Middleton R, Hahn CG, Xu B, Van Meter PE, Katechis M, Rosenfield D.
    JAMA Psychiatry; 2022 Mar 01; 79(3):193-200. PubMed ID: 35080598
    [Abstract] [Full Text] [Related]

  • 13. Psychometric analysis of the Yale-Brown Obsessive-Compulsive Scale Second Edition Symptom Checklist.
    Storch EA, Larson MJ, Price LH, Rasmussen SA, Murphy TK, Goodman WK.
    J Anxiety Disord; 2010 Aug 01; 24(6):650-6. PubMed ID: 20471199
    [Abstract] [Full Text] [Related]

  • 14. The Suitability of Different Subtypes and Dimensions of Obsessive-Compulsive Disorder for Treatment with Anterior Capsulotomy: A Long-Term Follow-Up Study.
    Gong F, Li B, Zhang S, Wang Y, Gao Y, Xu Y, Wang X, Xiong B, Li D, Wen R, Qin Z, Wang W.
    Stereotact Funct Neurosurg; 2019 Aug 01; 97(5-6):319-336. PubMed ID: 31786574
    [Abstract] [Full Text] [Related]

  • 15. Myth of the pure obsessional type in obsessive--compulsive disorder.
    Williams MT, Farris SG, Turkheimer E, Pinto A, Ozanick K, Franklin ME, Liebowitz M, Simpson HB, Foa EB.
    Depress Anxiety; 2011 Jun 01; 28(6):495-500. PubMed ID: 21509914
    [Abstract] [Full Text] [Related]

  • 16. Obsessive-compulsive symptom dimensions in schizophrenia patients with comorbid obsessive-compulsive disorder.
    Faragian S, Pashinian A, Fuchs C, Poyurovsky M.
    Prog Neuropsychopharmacol Biol Psychiatry; 2009 Aug 31; 33(6):1009-12. PubMed ID: 19447155
    [Abstract] [Full Text] [Related]

  • 17. Change in obsessive-compulsive symptoms mediates subsequent change in depressive symptoms during exposure and response prevention.
    Zandberg LJ, Zang Y, McLean CP, Yeh R, Simpson HB, Foa EB.
    Behav Res Ther; 2015 May 31; 68():76-81. PubMed ID: 25824533
    [Abstract] [Full Text] [Related]

  • 18. The Brief Obsessive-Compulsive Scale (BOCS): a self-report scale for OCD and obsessive-compulsive related disorders.
    Bejerot S, Edman G, Anckarsäter H, Berglund G, Gillberg C, Hofvander B, Humble MB, Mörtberg E, Råstam M, Ståhlberg O, Frisén L.
    Nord J Psychiatry; 2014 Nov 31; 68(8):549-59. PubMed ID: 24568661
    [Abstract] [Full Text] [Related]

  • 19. Perceived parental rearing style in obsessive-compulsive disorder: relation to symptom dimensions.
    Alonso P, Menchón JM, Mataix-Cols D, Pifarré J, Urretavizcaya M, Crespo JM, Jiménez S, Vallejo G, Vallejo J.
    Psychiatry Res; 2004 Jul 15; 127(3):267-78. PubMed ID: 15296826
    [Abstract] [Full Text] [Related]

  • 20. Six-month follow-up of a randomized controlled trial augmenting serotonin reuptake inhibitor treatment with exposure and ritual prevention for obsessive-compulsive disorder.
    Foa EB, Simpson HB, Liebowitz MR, Powers MB, Rosenfield D, Cahill SP, Campeas R, Franklin M, Hahn CG, Hembree EA, Huppert JD, Schmidt AB, Vermes D, Williams MT.
    J Clin Psychiatry; 2013 May 15; 74(5):464-9. PubMed ID: 23759449
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.